Published in Am J Cardiol on February 08, 2006
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag (2008) 1.30
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci (2015) 1.25
Genetic determinants of statin intolerance. Lipids Health Dis (2007) 1.15
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther (2014) 1.10
Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc (2010) 1.06
Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep (2010) 1.05
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol (2009) 1.01
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc (2010) 0.97
Muscular effects of statins in the elderly female: a review. Clin Interv Aging (2013) 0.96
Protective effects of coenzyme q(10) on decreased oxidative stress resistance induced by simvastatin. J Clin Biochem Nutr (2007) 0.94
Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J (2015) 0.92
Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol (2014) 0.92
Intolerance to statins: mechanisms and management. Diabetes Care (2013) 0.87
Nanotechnology for synthetic high-density lipoproteins. Trends Mol Med (2010) 0.86
Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag (2008) 0.86
Safety of statins: an update. Ther Adv Drug Saf (2012) 0.86
Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism. Indian J Crit Care Med (2016) 0.84
Rosuvastatin-induced acute interstitial nephritis. Case Rep Nephrol Urol (2013) 0.81
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res (2010) 0.81
Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman. Oman Med J (2014) 0.80
Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO. Steroids (2012) 0.79
Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia. Clin Med Insights Endocrinol Diabetes (2012) 0.79
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian J Med Res (2013) 0.79
The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med (2016) 0.77
Molecular mechanisms of statin intolerance. Arch Med Sci (2016) 0.77
Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients. Can J Cardiol (2009) 0.76
Management of intracerebral hemorrhage-use of statins. Vasc Health Risk Manag (2016) 0.75
Rhabdomyolysis induced acute renal failure secondary to statins. Indian J Nephrol (2013) 0.75
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag (2007) 0.75
Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients. J Can Chiropr Assoc (2010) 0.75
Cholesterol lowering for secondary prevention: what statin dose should we use? Vasc Health Risk Manag (2007) 0.75
The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1. Sci Rep (2016) 0.75
Potential drug interactions with statins: Estonian register-based study. Open Med (Wars) (2015) 0.75
Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. Eur J Clin Pharmacol (2016) 0.75
Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism. Lipids Health Dis (2017) 0.75
The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells. Lipids Health Dis (2014) 0.75
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient (2016) 0.75
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag (2013) 0.75
Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. J Clin Med Res (2017) 0.75
No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus Casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial. Chin J Integr Med (2016) 0.75
Evaluation of medication compliance for secondary prevention of acute coronary syndrome. Proc (Bayl Univ Med Cent) (2017) 0.75
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep (2017) 0.75
Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One (2017) 0.75